Has Uloma Labrie received payments from drug or device companies?

Yes. Drug and device makers reported $1,839 in general payments to Uloma Labrie across 69 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Uloma Labrie did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Uloma Labrie come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Uloma Labrie

Neurodevelopmental Disabilities · Dallas, TXNPI 1932768389

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by UCB, Inc. at 38.4% of the total.

$1,839in general payments, 2019–2025

Across 69 payments — averaging $26.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

UCB, Inc.$705
Jazz Pharmaceuticals Inc.$192
SK Life Science, Inc.$183
Novartis$156
Argenx US, Inc.$68
Amylyx Pharmaceuticals, Inc.$54
plus $481 from 17 others

What the payments were for

Food & beverage$1,839100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
UCB, Inc.	26	$705
Jazz Pharmaceuticals Inc.	5	$192
SK Life Science, Inc.	6	$183
Novartis	3	$156
Argenx US, Inc.	3	$68
Amylyx Pharmaceuticals, Inc.	2	$54
AstraZeneca(2 entities)	2	$48
Merz Pharmaceuticals, LLC	2	$47
Eisai Inc.	2	$45
Chiesi USA, Inc.	2	$44
Neurocrine Biosciences, Inc.	2	$33
Greenwich Biosciences, Inc.	2	$33
Livanova USA, Inc.	2	$32
Amgen	1	$25
Neurelis, Inc.	1	$25
Novo Nordisk	1	$22
Takeda Pharmaceuticals U.S.A., Inc.	1	$21
Catalyst Pharmaceuticals, Inc.	1	$21
Nevro Corp.	1	$20
NS Pharma, Inc.	1	$18
Sanofi	1	$17
Pfizer	1	$16
Novocure Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neurodevelopmental disabilities providers in Texasto place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Amitriptyline Hcl	13	$150

Paid to pharmacies, not to this prescriber.

Other neurodevelopmental disabilities in Dallas

Linda NguyenDallas$526
Delaney DowdDallas$63
Kendall BrownDallas$47
Rafael MimbelaDonna$10K
Satish AgadiGalveston$8K
Rafael Villalobos-NietoHarlingen$8K
Saeed KahkeshaniBaytown$3K
Pamela LupoWebster$2K
Vanessa Caress Mbanga TchakountePasadena$319
Katrina Willie-MusomaMansfield$172

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →